about
Discovery and validation of new potential biomarkers for early detection of colon cancerThe European panel on the appropriateness of gastrointestinal endoscopy guidelines colonoscopy in an open-access endoscopy unit: a prospective study.Thiopurine Therapy Reduces the Incidence of Colorectal Neoplasia in Patients with Ulcerative Colitis. Data from the ENEIDA Registry.Colorectal cancer: from prevention to personalized medicine.Relationship between methylation and colonic inflammation in inflammatory bowel disease.Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer.Mechanisms of colon cancer prevention with and beyond COX-2 inhibition.Colorectal Cancer Screening Programme in Spain: Results of Key Performance Indicators After Five Rounds (2000-2012).Risk Model for Colorectal Cancer in Spanish Population Using Environmental and Genetic Factors: Results from the MCC-Spain study.Increased Risk of Colorectal Cancer in Patients With Multiple Serrated Polyps and Their First-Degree Relatives.The fecal hemoglobin concentration, age and sex test score: Development and external validation of a simple prediction tool for colorectal cancer detection in symptomatic patients.Aberrant gene expression in mucosa adjacent to tumor reveals a molecular crosstalk in colon cancer.Nanofluidic digital PCR for KRAS mutation detection and quantification in gastrointestinal cancer.False-negative rate cannot be reduced by lowering the haemoglobin concentration cut-off in colorectal cancer screening using faecal immunochemical test.Prescription drugs associated with false-positive results when using faecal immunochemical tests for colorectal cancer screening.Colorectal cancer risk factors in patients with serrated polyposis syndrome: a large multicentre study.Endoscopic surveillance in patients with multiple (10-100) colorectal polyps.Corrigendum: Risk Model for Colorectal Cancer in Spanish Population Using Environmental and Genetic Factors: Results from the MCC-Spain study.[Fecal calprotectin in the diagnosis of inflammatory bowel diseases].Colonoscopy quality assessment in a mass population screening programme based on faecal occult blood test.Novel methylation panel for the early detection of neoplasia in high-risk ulcerative colitis and Crohn's colitis patients.Reply to Dr. Papamichael et al.'s letter.DNA methylation biomarkers for noninvasive diagnosis of colorectal cancer.An urgent referral strategy for symptomatic patients with suspected colorectal cancer based on a quantitative immunochemical faecal occult blood test.External Evaluation of Population Pharmacokinetic Models of Infliximab in Patients With Inflammatory Bowel Disease.Risk of colectomy in patients with ulcerative colitis under thiopurine treatment.[Management of acute lower gastrointestinal hemorrhage: position statement of the Catalan Society of Gastroenterology].A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease.Endoscopic requirements of colorectal cancer screening programs in average-risk population. Estimation according to a Markov model.Prevalence and characteristics of MUTYH-associated polyposis in patients with multiple adenomatous and serrated polyps.Post-operative morbidity and mortality of a cohort of steroid refractory acute severe ulcerative colitis: Nationwide multicenter study of the GETECCU ENEIDA Registry.[Hyperplastic polyposis syndrome: phenotypic diversity and association to colorectal cancer].Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel diseaseCyclooxygenase 2 Expression in Colorectal Cancer with DNA Mismatch Repair DeficiencyHigh incidence of advanced colorectal neoplasia during endoscopic surveillance in serrated polyposis syndromeProton pump inhibitors reduce the accuracy of faecal immunochemical test for detecting advanced colorectal neoplasia in symptomatic patientsGenomic rearrangements in MSH2 and MLH1 are rare mutational events in Spanish patients with hereditary nonpolyposis colorectal cancer[Long-term results of emergency surgery for colon cancer compared with elective surgery]Late-occurring liver metastases in colorectal cancerPostoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial
P50
Q21131953-84F5581B-ADB9-4A2F-A23A-5290F33E7C58Q30482833-67E3EC04-B309-43B1-A37F-8902A9C8FA76Q30992292-CBB04865-CC25-482D-B2B7-119F803A8562Q33735234-62E14988-5DF0-41AC-AEF7-B660F93C5166Q34036817-1FE71028-6A99-4177-A1EF-C7E2CE4C7BDBQ34414061-BE262F64-18C7-4E37-B3C8-CC29A14162A3Q36172773-4EE71227-0668-48F7-8E8C-4F9BF49F18D9Q36500818-0F65657B-8718-482F-A95E-4B9FC8119829Q37663150-08ED9D49-BEFC-45F0-80B3-6222CDE3CEA1Q38841697-DAEDCA81-5D19-406C-BAE8-860649BA0B55Q38967053-B9CACCB8-AF8D-4417-9F63-5E9100DB2510Q39682144-0E4DE5D3-7D6D-4853-A13C-89F2A1743C25Q40045042-8C94530B-46CA-4EF5-8BD7-CDB2179C890DQ40643881-5E89D63F-8EE1-423A-A5D9-0023C054907BQ40667101-75A43F66-BEBB-4224-B56A-146A6559D7E8Q41492470-DCC28DE8-0107-4562-94A6-AF4AB8F26457Q41593799-A02E7B3F-89AB-440F-82C8-9EEF0A37235DQ42039152-B334C09E-8C04-4865-B097-98536691A2A7Q43484265-1E90408E-0102-498D-AF80-26CC9C90008AQ44556441-F6A445AA-F9F8-46A4-AFE5-F0891FD9CB5AQ45121758-114C7FD9-AD65-4885-9ED3-50BA067AC19AQ45892503-AB6BEA0A-6121-403B-A4E2-F7E3D5474E2BQ46446012-8712BAEC-DDA4-4DCF-996B-342CC3ABB788Q48666318-03E919A8-FEEA-4EDE-AC09-0EB51FD8DF62Q50099434-91516D70-A7B9-49AD-A1CF-E8ACE3FF5196Q50473979-A494E9EE-4A93-4047-9E16-F45EE55C6BCCQ50489419-A8DD381A-44A9-42FE-852A-9CBC73AA9888Q50870630-7D80FD19-1A99-485B-B309-205CE92A226CQ51122394-20579914-1BA3-44DC-9D47-2CDB6BDE3DE6Q51756228-2C52C5B8-5A88-425E-87D0-B6EFEF2F0AB1Q54224335-1FAFD297-67A5-454B-BF7C-03B8D9DC3864Q54332049-5BD87450-4745-49CE-AB0C-5AA06F44E496Q57190076-25A397C5-2E65-4CED-86DB-45A89BAE01B6Q57239956-40C9AB43-FEA7-4445-A04B-30C7BF4432A4Q57550765-1F5C5940-1962-4D98-8BB7-CE9CCA222865Q58782521-07C88913-D9A0-400F-843E-C800EEB87227Q80347093-39EE1FFE-AB56-4386-9338-3FB5C255287BQ81037961-CDAE457F-D3E5-4211-BBF0-16214EE6E3F0Q81472910-51BC9D5C-0365-4677-BBC1-30E21443B918Q81645441-C4466FCF-09A5-45EF-9E05-7C1DE15DA994
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Francisco Rodríguez Moranta
@ast
Francisco Rodríguez Moranta
@en
Francisco Rodríguez Moranta
@es
Francisco Rodríguez Moranta
@nl
type
label
Francisco Rodríguez Moranta
@ast
Francisco Rodríguez Moranta
@en
Francisco Rodríguez Moranta
@es
Francisco Rodríguez Moranta
@nl
prefLabel
Francisco Rodríguez Moranta
@ast
Francisco Rodríguez Moranta
@en
Francisco Rodríguez Moranta
@es
Francisco Rodríguez Moranta
@nl
P106
P21
P31
P496
0000-0003-4025-5510